[The results of the 10-year study of efficacy and safety of Serenoa repens extract in patients at risk of progression of benign prostatic hyperplasia].

Abstract

The article presents the results of an open, noncomparative, observational study of the efficacy and safety of continued use of the Serenoa repens (prostamol uno) plant extract at a dose of 320 mg 1 time a day for 10 years in 38 patients with early manifestations of BPH and the risk of its progression. The results of study showed the absence of progression, both on subjective criteria (IPSS, and QoL scores), and objective criteria (prostate volume, the rate of urination, residual urine volume). Furthermore, patients had no undesirable effects directly related to the use of this drug.

• Authors: Iu G Aliaev, A Z Vinarov, Iu L Demidko, L G Spivak
• Journal: Urologiia (Moscow, Russia : 1999) (Urologiia) 2013 Jul-Aug Issue 4 Pg. 32-6 ISSN: 1728-2985 [Print] Russia (Federation)
• PMID: 24159762 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Plant Extracts
• Prostamol-Uno

Topics

• Disease Progression
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Humans
• Male
• Middle Aged
• Phytotherapy (methods)
• Plant Extracts (administration & dosage, adverse effects, therapeutic use)
• Prostatic Hyperplasia (drug therapy, physiopathology)
• Quality of Life
• Serenoa (chemistry)
• Time Factors
• Treatment Outcome
• Urodynamics (drug effects)